Locations

Ellis Fischel Cancer Center
1 Hospital Dr
Columbia, MO

Phone: 573-884-4854

Other Phone Numbers:

Phone: (573) 882-2100

Get Directions

University Hospital
1 Hospital Dr
Columbia, MO

Phone: 573-884-4854

Other Phone Numbers:

Phone: (573) 882-4141

Get Directions

1. Ellis Fischel Cancer Center

1 Hospital Dr
Columbia, MO
Phone: 573-884-4854
Other Phone Numbers:
Phone: (573) 882-2100
View Details
Get Directions

2. University Hospital

1 Hospital Dr
Columbia, MO
Phone: 573-884-4854
Other Phone Numbers:
Phone: (573) 882-4141
View Details
Get Directions

Profile

As a physician-scientist, Dr. Kevin Staveley-O'Carroll has acquired a broad experience in basic, clinical and translational research, with extensive knowledge and skill sets in cellular and molecular mechanisms of cancer biology and immunology. His goal is to translate basic research into clinical practice.

Gender

Male

Education & Training

Medical School

University of Oklahoma

Residency

General Surgery

  • Johns Hopkins University School of Medicine

Fellowship

Surgical Oncology

  • Johns Hopkins University School of Medicine

Boards

American Board of Surgery

Insurances

MU Health Care participates with most major managed care organizations. To find out whether MU Health Care is a participating provider in your insurance plan or network, or for information on co-payments and deductibles, please contact your insurance carrier directly.

In the News

After Trebek's Announcement, A Glimmer of Hope for a Deadly Disease

Academic Information

Hugh E. Stephenson Jr., MD, Chair, Department of Surgery
Director of Ellis Fischel Cancer Center

Research Profile

Dr. Staveley-O'Carroll currently is the PI for a phase 2 clinical trial investigating Poly-ICLC in the treatment of solid cancers (NCT02423863). Previously, he served as PI for an investigator-initiated phase 1 trial studying the effects of intra-tumoral injection of Poly-ICLC and adoptively transferred dendritic cells in patients with pancreatic adenocarcinoma (NCT01677962). His ongoing R01 grant is funded by the NIH to elucidate the cellular and molecular mechanisms by which chemotherapeutic agents and nanoparticles, prevent immunotolerance and enhance T cell-mediated immunotherapy. He also serves as a PI on a VA Merit Award investigating the effect of radiofrequency ablation after manipulating the tumor microenvironment in our novel model of murine HCC.

Research Interests

  • Clinical trials
  • Tumor‐induced immunotolerance
  • Liver cancer
  • Pancreatic cancer
  • Immunotherapy
  • Crosstalk of gut microbiome and diet in liver fibrosis and liver cancer
  • Animal tumor models

Areas of Expertise

  • Translational research
  • Immunology
  • Cancer
  • Liver disease